Onkológia 6/2017

Enzalutamide in treatment of the metastatic castration resistant prostate cancer

Prostate cancer (PC) is extremely complicated and interindividual different tumour. The methods of treatment depends on several factors, but mainly on the stage of PC. The standard treatment for metastatic PC is androgen deprivation therapy (ADT). Men with castrate resistant prostate cancer (CRPC) are quite a heterogeneous group. Historically, therapy had little effect beyond modest palliation. More recently, significantly more options have become available and there are now several treatment possibilities that not only improve quality of life and relief pain, but also increase overall survival. Enzalutamide is an androgen receptor signaling inhibitor, approved for the treatment of metastatic CRPC either prior to chemotherapy or after previous docetaxel treatment. The article provides an overview of the mechanism of action, efficacy, side effects as well as the perspective of CRPC treatment with using enzalutamide.

Keywords: castrate resistant prostate cancer, enzalutamide, efficacy, safety, perspectives